This article is more than 5 years old. Information may no longer be current.

RNAi technology for AMD begins phase 1 trial

Add topic to email alerts

Receive an email when new articles are posted on

Please provide your email address to receive an email when new articles are posted on .

Subscribe

Added to email alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

Back to Healio

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Back to Healio

An RNA interference compound to treat age-related macular degeneration has begun a phase 1 trial, according to Sirna Therapeutics, the developer of the compound.

Sirna-027 will be evaluated at four U.S. research centers in the treatment of up to 30 patients with wet AMD. This initial dose-ranging trial will measure the safety, tolerability and biological activity of the compound following a single intravitreal injection, Sirna announced in a press release.

According to the company, Sirna-027 is the first chemically modified short interfering RNA compound that targets vascular endothelial growth factor receptor-1. Based on Sirna’s projected timeline, preliminary results are expected by the third quarter of 2005.